This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
These therapies have broadened treatment options for patients to expand beyond the more traditional smallmolecule drug alternatives. Patients and caregivers also assess the benefits offered by different therapies, weighing the progression-free survival with their off-target effects.
By Allessandra DiCorato October 4, 2023 Credit: AbbVie The new smallmolecule inhibitor (green) sits inside the PTPN2 protein, where acidic sites are marked in red and basic sites are marked in blue. A new small-molecule drug candidate being tested in an early-stage clinical trial aims to improve patient responses to immunotherapy.
Most targeted cancer therapies used today operate by inhibiting targets along well-known oncogenic signalling cascades. The reactivation of oncogenic signalling upstream or downstream of the driving oncogene is a well-studied source of resistance to targeted cancer therapies.
These are incredible forecasts and CAGRs, which if we assume directionally correct, rely not only on steady growth for approved therapies but also a substantial success rate of, and continued investment in, the development pipeline. Smallmolecule GLP1s?
Groundbreaking strategies like proteolysis-targeting chimeric molecules (PROTACs) are also being explored. 6 Combining the effect of payloads with different mechanisms of action – an approach that revolutionised smallmolecule chemotherapy – also holds the promise of enhanced therapeutic activity for ADCs.
Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists.
We look forward to working on this new collaboration with Biohaven, a world leader in the clinical development of CGRP-targeted therapies.”
TOKYO and CAMBRIDGE, England , Dec. Vlad Coric , M.D.,
The acquisition strengthens BioNTech’s cell therapy pipeline by accelerating the individualized solid tumor Neoantigen TCR cell therapy research and development program. It also expands the Company’s cell therapy capabilities and manufacturing footprint in North America, building on its acquisition of Neon Therapeutics in 2020.
There are no current smallmoleculetherapies targeting the underlying cause of the disease, leaving a high unmet need for medications that can be used for treating or ameliorating HD. Consequently, there remains a need to identify and provide smallmolecule compounds for treating or ameliorating HD. 2020-01-02.
Vertex Pharmaceuticals has decided to give up on its experimental VX-814, a smallmolecule drug for the rare genetic disease Alpha-1 antitrypsin deficiency (AATD), canning the drug’s development after seeing lackluster results from an early phase 2 trial. James Miessler.
27, 2020 /PRNewswire/ — Mirati Therapeutics, Inc. The offering is expected to close on or about October 30, 2020 , subject to customary closing conditions. Adagrasib is an investigational smallmolecule and selective KRAS G12C inhibitor in clinical development as a monotherapy and in combinations. SAN DIEGO , Oct.
Presentations to highlight the OBI-833 Phase 1 clinical study results in non-small cell lung cancer (NSCLC) and the dose escalation cohort. 19, 2020 /PRNewswire/ — OBI Pharma, Inc. Session Date and Time: Friday, November 20, 2020. Session Date and Time: Friday, November 20, 2020. TAIPEI, Taiwan , Nov.
TEAD proteins are known to be very important in cancer progression TEAD proteins are known to be very important in cancer progression, and there are a number of therapies in development. Can you provide a summary of the key findings and implications of the preclinical studies on ISM6331 for the treatment of advanced solid tumours?
The Atlas of MS reported in 2020 that someone is diagnosed with MS every five minutes around the world, adding to about 2.8 While no cure is available for MS, existing disease-modifying therapies in the form of smallmolecule and protein drugs either directly target the self-reactive immune cells or broadly dampen inflammation.
27, 2020 /PRNewswire/ — Aridis Pharmaceuticals, Inc. ” Panel: Direct Antivirals and Other Agents Against SARS-CoV2 Virus
Date: Wednesday, October 28, 2020
Time: 10:30AM- 11:50AM ET. SAN JOSE, Calif. , The Company’s pipeline is highlighted below: Aridis’ Pipeline.
3, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) announced financial results for the fourth quarter and full year ended December 31, 2020. AbbVie hosted an Immunology Strategic Update event on December 14, 2020 for members of the investment community. NORTH CHICAGO, Ill., Gonzalez , chairman and chief executive officer, AbbVie.
While the development of smallmolecule drugs targeting GPCRs, the development of monoclonal antibody drugs has also received great attention. Due to the relatively small extracellular domain of GPCR, complex signal activation, and the relatively large structure of traditional IgG antibodies, it is very difficult to develop.
22, 2020 02:59 UTC. Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the pricing of its public offering of 14,000,000 shares of its common stock at a public offering price of $3.00 EVANSTON, Ill.–( About Aptinyx.
12, 2020 14:00 UTC. As an orally bioavailable smallmolecule with broad antiviral activity, SLV213 could be a valuable treatment to meet today’s urgent need to fight COVID-19 as well other life-threatening infectious diseases, such as Chagas disease, Ebola virus disease, and Nipah virus infection.”. About SLV213.
“More than 10 million people worldwide are affected by Parkinson’s disease, and there is a significant medical need for therapies to slow or stop the progression of this devastating neurodegenerative disease,” said Carole Ho, M.D., BIIB122 is an investigational smallmolecule inhibitor of LRRK2 that was discovered and developed by Denali.
This collaboration combines Alectos’ expertise in small-molecule therapeutics with Biogen’s development capabilities in movement disorders. Currently, there are no approved disease modifying therapies for PD, creating significant unmet needs for patients seeking to slow disease progression.
Smallmolecule candidate Anle138b targets disease modification for multiple system atrophy and other neurological disorders. With the introduction of small-molecule medication, we open a new chapter in the fight against neurodegenerative diseases and have the chance to improve the lives of millions of patients drastically.”.
The study enrolled 5,050 patients who received either vericiguat or placebo in combination with available heart failure therapies. On December 17, 2020, Aurinia inked a collaboration and license deal with Japan’s Otsuka Pharmaceutical Co. HFrEF was formerly known as systolic heart failure.
Therapies developed in recent decades have transformed the treatment of IBD, making hospitalisation and surgery less common. However, many patients respond poorly to corticosteroid treatment, or their immune system responds unfavourably to biological therapies, such as the development of autoimmune diseases.
Science, 2020 We now know that the immune system of nearly everyone who recovers from COVID-19 produces antibodies against SARS-CoV-2, the novel coronavirus that causes this easily transmitted respiratory disease [1]. Preprint Posted May 5, 2020. [2] So, what exactly led up to this latest scientific achievement?
Convergent has exclusive rights to technology related to next generation radiopharmaceutical therapy for prostate cancer that is covered by multiple issued U.S.
The key component of Convergent’s PRRT prostate cancer therapy is its proprietary drug, CONV 01-?, and foreign patents.
The function of CONV 01-?
24, 2020 07:05 UTC. OSLO, Norway–( BUSINESS WIRE )– Ultimovacs ASA (“Ultimovacs”, ticker ULTIMO), today announced that Ton Berkien will join Ultimovacs’ management team as Chief Business Officer (CBO), effective December 1, 2020. For further information, please see www.ultimovacs.com.
TCR 2 is developing novel T-cell therapies for solid tumors and hematological cancers. The company is using its pioneering FasTCAR and TruUCAR technology platforms to discover and develop breakthrough cell therapies. Its lead candidate is CLN-081, an oral smallmolecule designed to be a next-generation, irreversible EGFR inhibitor.
BioNTech SE (NASDAQ: BNTX, “BioNTech” or “the Company”), announced that the first patient has been treated in its BNT111 Phase 2 cancer vaccine trial (2020-002195-12; NCT04526899). These results were published in Nature in July 2020.
Sixty-two percent of patients were treated with prior PD(L)-1 containing therapy, and the arms were well balanced. More financial details will be provided by the company in its fourth quarter 2020 financial report in March 2021. SOUTH SAN FRANCISCO, Calif., Median PFS was 9.2 months with cabozantinib and placebo. Exelixis, Inc.
Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial to evaluate IDE397, a smallmolecule methionine adenosyltransferase 2a (MAT2A) inhibitor, for the treatment of patients having solid tumors with methylthioadenosine phosphorylase (MTAP) deletion. Chief Scientific Officer, IDEAYA Biosciences.
16, 2020 09:20 UTC. Existing therapies to treat TRK fusions have elicited modest on-target adverse effects, including dizziness and weight gain. SAN DIEGO–( BUSINESS WIRE )– Cullgen Inc. , In addition, acquired drug resistance has been reported in patients after treatment with approved TRK protein inhibitors.
Its application has the potential to enable smaller and faster trials, and thus deliver innovative therapies to a broad population years faster than otherwise would be possible. We’ve made a very potent liver-targeted oral smallmolecule drug,” Dobmeier said. Coming off 2020, there’s a lot to execute on.
Chiauranib as a single agent therapy inhibits the overactive Aurora B pathway existed in and related to molecular mechanism of SCLC, which is an important feature of Chiauranib distinct to other antiangiogenic drugs. SH ) was founded in Shenzhen on 2001, specializing in the research and development of novel smallmolecule drugs.
09, 2020 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. The closing of the offering is expected to occur on or about December 14, 2020, subject to satisfaction of customary closing conditions. SAN DIEGO, Dec. per share, less underwriting discounts and commissions. per share, less underwriting discounts and commissions.
19, 2020 08:02 UTC. Dr. Berk most recently has served as a consultant to several companies developing oncology therapies. Inflection Biosciences Ltd is developing smallmolecule therapeutics for the treatment of cancer. Berk, MD, to its Board of Directors. About Inflection Biosciences.
15, 2020 /PRNewswire/ — Lantern Pharma (NASDAQ: LTRN ), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) At the stage of GBM relapse and recurrence, no effective therapy strategies currently exist.
.
DALLAS , Dec.
Contact.
11, 2020 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. , (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel smallmolecule drugs for the treatment of cancer and other life-threatening diseases, today announced its participation at two upcoming healthcare investor conferences in November.
22, 2020 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. , Importantly, the manufacturing process for our smallmolecule direct-acting antiviral allows us to produce AT-527 quickly and at scale.”. BOSTON, Oct. “The ongoing complexities of COVID-19 require multiple lines of defence. ” About AT-527.
It works as a colony-stimulating factor 1 ( CSF1 ) receptor inhibitor. [1] It works as a colony-stimulating factor 1 ( CSF1 ) receptor inhibitor. [1] CSF1R inhibitor BLZ945 selectively binds to CSF1R expressed on tumor-associated macrophages (TAMs), blocks the activity of CSF1R, and inhibits CSF1R-mediated signal transduction pathways.
15, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN) and MBC BioLabs today announced that BigHat Biosciences and Trilo Therapeutics have each been awarded an Amgen Golden Ticket to MBC BioLabs. We look forward to interacting with Amgen ‘s scientific and therapeutic experts to help move Trilomer® therapies into the clinic.
12, 2020– AstraZeneca and Alexion Pharmaceuticals, Inc. AstraZeneca has developed a broad range of technologies, initially focused on smallmolecules and biologics and with a growing focus in precision medicine, genomics, oligonucleotides and epigenetics. CAMBRIDGE, England & BOSTON –(BUSINESS WIRE)–Dec.
European Commission approves GSK’s JEMPERLI (dostarlimab), the first anti-PD-1 therapy approved for recurrent or advanced endometrial cancer. The approval makes dostarlimab the first anti-PD-1 therapy available for endometrial cancer in Europe. Hormone replacement therapy for endocrinopathies should be instituted as warranted.
29, 2020 /PRNewswire/ — Ascentage Pharma (6855.HK), 1 Meanwhile, these MDM2 inhibitors present some challenges, including dose-limiting hematological toxicities, thus the urgent need to develop new generation of MDM2-targeting therapies in the treatment of cancer. SUZHOU, China and ROCKVILLE, Md. , Aguilar, A.; Bernard, D.;
Most recently ( June 2020 ) FUJIFILM Corporation invested 100 billion yen ( 928 million USD ) in FUJIFILM Diosynth Biotechnologies’ Hillerød, Denmark site to double its large-scale cell culture manufacturing capacity and add commercial scale drug product production capabilities. Overview of New Site.
1.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content